Dr. Vicky Makker, MD

Dr. Makker practices at Memorial Sloan Kettering Cancer Center in New York, New York, part of Memorial Sloan Kettering Cancer Center.

Dr. Makker's NPI, 1972769800, was assigned on July 30, 2008. Dr. Makker graduated from University of Florida College of Medicine in 2003. Dr. Makker holds New York license 239045-1.

Dr. Makker's primary practice is Memorial Sloan Kettering Cancer Center, at 1275 York Avenue, New York, NY 10065.

Dr. Makker's primary practice is Memorial Sloan Kettering Cancer Center in New York, New York, part of Memorial Sloan Kettering Cancer Center. The medical group on file is Memorial Sloan Kettering Cancer Center. Dmand AI also links Dr. Makker to 2 more home health agencies, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Makker practices, 3 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Makker's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Makker is licensed in New York.

Dmand AI lists breast cancer, chronic leukemia and lung cancer among the conditions Dr. Makker treats.

CMS data shows 487 Medicare services from Dr. Makker across 2 procedure codes in 2024, all of them office visits, for 137 Medicare patients. Medicare paid $43,934 for them. Every service was in an office.

CMS counts 137 Medicare patients who saw Dr. Makker in 2024. The largest group is 65 to 74, with 66 patients. 74% of them have cancer, and 72% have high blood pressure. 16% are also on Medicaid. Their average risk score is 2.60, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Makker's median patient age at 72, with 99% women.

In 2024, Dr. Makker wrote 542 Medicare Part D claims for 94 patients. 87% of them were for generic drugs. CMS names the drug for 339 of them, across 19 drugs with 11 or more claims each, at $11,786 in total drug cost. In 2023, CMS named 346 claims across 15 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 78 out of 100 for Dr. Makker for performance year 2024, reported as part of a group. Dr. Makker accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Makker as offering telehealth.

Dmand AI links 104 papers to Dr. Makker, published from 2008 to 2025. 2024 was the busiest year, with 14. The most frequent topics are Endometrial Neoplasms, Antineoplastic Combined Chemotherapy Protocols and Ovarian Neoplasms. Dr. Makker has published most often in Gynecol Oncol. Dr. Makker's most frequent co-authors are Carol Aghajanian, MD, Nadeem R. Abu-Rustum, MD and Kaled M. Alektiar, MD.

CMS Open Payments shows 48 general payments to Dr. Makker from 5 drug and device companies from 2017 to 2024. Travel and lodging make up the largest share, 85% of the total. Merck Sharp & Dohme Corporation paid the most, $39,825.

Dr. Makker graduated from University of Florida College of Medicine in 2003.

Dr. Makker is in network with 12 carriers, including Aetna, Excellus BlueCross BlueShield and United Healthcare. PPO plans come from the most carriers, 8. Check the plan with the practice before a visit.